{"id":47451,"date":"2017-08-01T07:00:45","date_gmt":"2017-08-01T11:00:45","guid":{"rendered":"https:\/\/asweetlife.org\/?p=47451"},"modified":"2017-08-03T19:25:43","modified_gmt":"2017-08-03T23:25:43","slug":"bigfoot-biomedical-ditches-dexcom-cgm-for-abbott","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=47451","title":{"rendered":"Bigfoot Biomedical Chooses Abbott’s Libre Over Dexcom’s CGM"},"content":{"rendered":"

Bigfoot Biomedical has a lot going for it. It\u2019s got intrigue (read the story<\/a> about its co-founder Bryan Mazlish in Wired); it has respected industry executives (co-founder Jeffrey Brewer was the president of JDRF<\/a> for four years); and it has guts (to grapple with getting FDA approval for a brand new concept\u2013\u2013the artificial pancreas\u2013\u2013well, that takes a lot of guts).<\/p>\n

After two and a half years of development, during which the company has raised over $40M in funding, the company has rejected one of the most respected names in diabetes tools\u2013\u2013Dexcom\u2013\u2013to partner with Abbott Laboratories for its initial launch. It\u2019s not easy to make technology changes but Brewer, the CEO of Bigfoot<\/a>, felt the switch was crucial. The difference in the two products came down to calibration and accuracy.<\/p>\n

\u201cA lot of people calibrate the sensor with the sensor,\u201d says Brewer. \u201cOur data says this happens a lot. If you can take the calibration step out, you don\u2019t have the risk of a bad number,\u201d says Brewer. He also found the insertion process of the FreeStyle\u00ae Libre<\/a>, which has only one unit, to be elegant. \u201cIt\u2019s consistent with our product vision,\u201d says the CEO. \u201cWe picked the thing that will work best for Bigfoot. Dexcom makes a good sensor, but competition drives innovation.\u201d<\/p>\n

Jared Watkin, divisional vice president of R&D at Abbott, was thrilled to have the partnership come together. While many outside regarded the move (announced<\/a> on July 13th) as a validation for Libre, Watkin already had it. \u201cThe 300,000 people using Libre around the world is our clear sign,\u201d he says. \u201cWere we pleased? Of course.\u201d But the team at Abbott was already convinced that Libre was the right technology. While Bigfoot knew it wanted to switch, there were still some concerns that Abbott, which has 74,000 employees to Bigfoot\u2019s 50, wouldn\u2019t be able to move fast enough for the intrepid startup, but Watkin assured them it could.<\/p>\n

While Abbott is still working to get FDA approval in the U.S. for its FreeStyle Libre, the team is also working on next generations\u2013\u2013think real-time communications with alarms\u2013\u2013and this is what it will deliver to Bigfoot for the clinical trials, which are targeted for late 2018, a date that has bumped out a bit because of this shift in technology.<\/p>\n

\"Bigfoot<\/p>\n

According to Brewer, there will be about a dozen sites across the country hosting clinical trials. Because the company aims for wide adoption, the study will also include doctors and people who aren\u2019t pump savvy. \u201cIt needs to be simple and work in an environment where you don\u2019t have an endocrinologist,\u201d says Brewer. \u201cThat\u2019s never been done before. Whenever trials have been done they only use the most savvy individuals. But that\u2019s not the real world.\u201d Keep your eyes on clinicaltrials.gov<\/a> for the chance to sign up.<\/p>\n

Like many, Brewer got pulled into the diabetes world because his son was diagnosed with Type 1 in 2002. We won\u2019t tell you how challenging it is to be a child or a teenager or a young adult with diabetes, but it\u2019s from watching his own son struggle with managing his own care (and tools that failed) that Brewer honed in on what the diabetes community needs. (I was diagnosed when I was twelve.) Bigfoot\u2019s goals are simple: to build solutions that will blend into our lives with ease and be simple enough to prescribe and operate that they could be accessible to a broad population.<\/p>\n

\u201cMy son doesn\u2019t want to be reminded that he has type one diabetes,\u201d says Brewer. \u201cHe needs something simpler and easier\u2013\u2013a consumer product, not a medical device. He needs Bigfoot.\u201d Let\u2019s hope with this new collaboration that the Bigfoot team is one step closer to the prize.<\/p>\n","protected":false},"excerpt":{"rendered":"

…<\/p>\n","protected":false},"author":232,"featured_media":47456,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1448],"tags":[],"yoast_head":"\nBigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM | ASweetLife<\/title>\n<meta name=\"description\" content=\"Bigfoot Biomedical has rejected one of the most respected names in diabetes tools\u2013\u2013Dexcom\u2013\u2013to partner with Abbott Laboratories for its initial launch.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=47451\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Larissa Zimberoff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=47451\",\"url\":\"https:\/\/asweetlife.org\/?p=47451\",\"name\":\"Bigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM | ASweetLife\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47451#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47451#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg\",\"datePublished\":\"2017-08-01T11:00:45+00:00\",\"dateModified\":\"2017-08-03T23:25:43+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/66727059a59313c4f549beae0c1fceb1\"},\"description\":\"Bigfoot Biomedical has rejected one of the most respected names in diabetes tools\u2013\u2013Dexcom\u2013\u2013to partner with Abbott Laboratories for its initial launch.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47451#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=47451\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=47451#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg\",\"width\":1110,\"height\":1125,\"caption\":\"Bigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=47451#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bigfoot Biomedical Chooses Abbott’s Libre Over Dexcom’s CGM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/66727059a59313c4f549beae0c1fceb1\",\"name\":\"Larissa Zimberoff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c4b44e0f01d6c2d24be23341f293e3fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c4b44e0f01d6c2d24be23341f293e3fe?s=96&d=mm&r=g\",\"caption\":\"Larissa Zimberoff\"},\"description\":\"Larissa Zimberoff was diagnosed with type 1 diabetes when she was 12-years old. She is an avid cyclist and a passionate supporter of bike lanes, free WiFi and the Affordable Care Act. She lives in New York City and writes about the intersection of food and technology. You can follow her on Twitter or read more of her published work\",\"url\":\"https:\/\/asweetlife.org\/?author=232\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM | ASweetLife","description":"Bigfoot Biomedical has rejected one of the most respected names in diabetes tools\u2013\u2013Dexcom\u2013\u2013to partner with Abbott Laboratories for its initial launch.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=47451","twitter_misc":{"Written by":"Larissa Zimberoff","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=47451","url":"https:\/\/asweetlife.org\/?p=47451","name":"Bigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM | ASweetLife","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=47451#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=47451#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg","datePublished":"2017-08-01T11:00:45+00:00","dateModified":"2017-08-03T23:25:43+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/66727059a59313c4f549beae0c1fceb1"},"description":"Bigfoot Biomedical has rejected one of the most respected names in diabetes tools\u2013\u2013Dexcom\u2013\u2013to partner with Abbott Laboratories for its initial launch.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=47451#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=47451"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=47451#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157.jpg","width":1110,"height":1125,"caption":"Bigfoot Biomedical Chooses Abbott's Libre Over Dexcom's CGM"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=47451#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Bigfoot Biomedical Chooses Abbott’s Libre Over Dexcom’s CGM"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/66727059a59313c4f549beae0c1fceb1","name":"Larissa Zimberoff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c4b44e0f01d6c2d24be23341f293e3fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c4b44e0f01d6c2d24be23341f293e3fe?s=96&d=mm&r=g","caption":"Larissa Zimberoff"},"description":"Larissa Zimberoff was diagnosed with type 1 diabetes when she was 12-years old. She is an avid cyclist and a passionate supporter of bike lanes, free WiFi and the Affordable Care Act. She lives in New York City and writes about the intersection of food and technology. You can follow her on Twitter or read more of her published work","url":"https:\/\/asweetlife.org\/?author=232"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47451"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/232"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47451"}],"version-history":[{"count":9,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47451\/revisions"}],"predecessor-version":[{"id":47467,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47451\/revisions\/47467"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/47456"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}